Table 4 Prognosis of KRAS mutant NSCLC received chemotherapy treatment
Characteristics and treatment scheme | Univariate analysis | Multivariate analysis | Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|---|---|---|
Median PFS (95%CI) (month) | P value | HR(95%CI) | P value | Median OS (95%CI)(month) | P value | HR(95%CI) | P value | |
Age (year) |  | 0.61 | – |  | 0.414 | – | ||
  < 65 | 8.7 (6.9–10.8) |  |  |  | 14.6 (9.7–19.6) |  |  |  |
  ≥ 65 | 9.1 (6.5–11.7) |  |  |  | 15.9 (14.6–17.2) |  |  |  |
Sex |  | 0.337 | 0.810(0.387–1.696) | 0.576 |  | 0.544 | 0.488(0.205–1.16) | 0.104 |
 Male (n=) | 7.0 (5.5–8.5) |  |  |  | 14.0 (11.7–16.3) |  |  |  |
 Female | 9.0 (4.1–13.9) |  |  |  | 15.9 (13.7–18.2) |  |  |  |
Smoking history |  | 0.847 | – |  | 0.843 | – | ||
 Yes | 7.0 (5.4–8.6) |  |  |  | 15.0 (12.2–17.8) |  |  |  |
 No | 6.0 (1.4–10.6) |  |  |  | 13.6 (10.8–16.4) |  |  |  |
Histology |  | 0.607 | – |  | 0.960 | – | ||
 Adenocarcinoma | 9.4 (7.8–11.1) |  |  |  | 14.3 (11.8–16.9) |  |  |  |
 Squamous | 10.7 (5.0–16.5) |  |  |  | 14.6 (0–34.8) |  |  |  |
KRAS mutant subtypes |  | 0.746 | 1.765(0791–3.939) | 0.165 |  | 0.510 | 2.110 (0.808–5.506) | 0.127 |
 G12C | 7.0 (3.2–10.8) |  |  |  | 13.6 (4.0–23.2) |  |  |  |
 non-G12C | 7.0 (5.4–8.6) |  |  |  | 15.0 (13.0–17.0) |  |  |  |
PD-L1 expression |  | 0.271 | 1.027(0.417–2.526) | 0.954 |  | – | 0.515(0.168–1.580) | 0.246 |
  < 1% | 10.1(3.6–16.6) |  |  |  | NA |  |  |  |
  ≥ 1% | 9.0 (5.8–12.2) |  |  |  | 23.8 (12.9–34.7) |  |  |  |
PS score |  | 0.811 | – |  | 0.408 | – | ||
 0–1 | 7.0 (1.5–8.5) |  |  |  | 14.3 (11.8–16.9) |  |  |  |
  = 2 | 6.0 (4.8–7.2) |  |  |  | 14.6 (10.7–18.6) |  |  |  |
Stage |  | 0.244 | – |  | 0.392 | – | ||
 III | 5.0 (1.5–8.5) |  |  |  | 10.0 (5.3–14.7) |  |  |  |
 IVa | 7.2 (4.6–9.8) |  |  |  | 15.0 (13.0–17.0) |  |  |  |
 IVb | 9.0 (4.5–13.5) |  |  |  | 15.0 (11.5–18.5) |  |  |  |
Chemotherapy drugs | 9.8 (6.6–13.1) | 0.041 | 0.434 (0.198–0.949) | 0.036 |  | 0.276 | 0.499 (0.202–1.232) | 0.132 |
 containing pemetrexed | 6.0 (5.1–6.9) |  |  |  | 16.4 (9.9–22.9) |  |  |  |
 containing paclitaxel | 5.0 (3.2–6.8) |  |  |  | 14.1 (11.5–16.7) |  |  |  |
Antiangiogenic therapy |  | < 0.001 | 0.307(0.117–0.805) | 0.016 |  | < 0.001 | 0.241(0.085–0.689) | 0.008 |
 Yes | 9.8 (8.4–11.2) |  |  |  | 20.0 (12.1–27.9) |  |  |  |
 No | 5.0 (3.2–6.8) |  |  |  | 10.0 (6.5–13.5) |  |  |  |